United Kingdom

Good momentum across all businesses and updated Generics guidance

Good momentum across all businesses and updated Generics guidance

AETOSWire April 29, 2023

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update...

Hikma strengthens US Injectables business through acquisition of Custopharm

Hikma strengthens US Injectables business through acquisition of Custopharm

Hikma strengthens US Injectables business through acquisition of Custopharm

AETOSWire April 12, 2023

Amman,Jordan, 12 April 2023 — Hikma Pharmaceuticals PLC (Hikma, Group), announces that Riad Mishlawi, President of the...

Hikma reiterates full year segmental guidance, with strong momentum in Injectables and Branded

Hikma reiterates full year segmental guidance, with strong momentum in Injectables and Branded

AETOSWire November 3, 2022

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update...

Collaboration between Al Hokair Group and IMPS to launch the first Smurfs FEC in the Mena region

Collaboration between Al Hokair Group and IMPS to launch the first Smurfs FEC in the Mena region

Collaboration between Al Hokair Group and IMPS to launch the first Smurfs FEC in the Mena region

AETOSWire October 19, 2022

ExCel London, United Kingdom — The recently concluded, Brand Licensing Europe tradeshow witnessed the signing of a license...

Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle East and North Africa region

Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle East and North Africa region

Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle East and North Africa region

AETOSWire July 18, 2022

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive licensing agreement...